Jazz Pharmaceuticals said solriamfetol (JZP-110) is a selective dopamine and norepinephrine reuptake inhibitor
(DNRI) in development for the treatment of excessive sleepiness in adult patients with narcolepsy, OSA, and Parkinson's disease.
Esbupropion is the S-enantiomer of bupropion, a dopamine and norepinephrine reuptake inhibitor
and nicotinic acetylcholine receptor antagonist which also serves to increase the bioavailability of dextromethorphan.
PARIS--Of patients with major depressive disorder who receive a selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrine reuptake inhibitor
(SNRI) as their initial pharmacotherapy, 40% do not achieve the minimum therapeutic dose within 4 weeks of diagnosis, according to a real-world study of U.
Strattera, a selective norepinephrine reuptake inhibitor
, is approved for both pediatric and adult patients.
Reboxetine (a-ariloxybenzyl derivative of morpholine) is a norepinephrine reuptake inhibitor
and also a norepinephrine transporter inhibitor, indicated in the therapy of unipolar depression, in panic and attention deficit hyperactivity disorders (4).
If SSRIs aren't effective, a serotonin and norepinephrine reuptake inhibitor
(SNRI) may be prescribed.
receptor, but also a serotonin and/or norepinephrine reuptake inhibitor
A third group took different antidepressants: venlafaxine (Effexor[R], a tetracyclic drug) and mirtazapine (Remeron[R], a serotonin norepinephrine reuptake inhibitor
, or SNRI).
Atomoxetine, a norepinephrine reuptake inhibitor
, was approved in 2002 as the first nonstimulant medication for attention-deficit/hyperactivity disorder (ADHD).
The drug, a selective serotonin norepinephrine reuptake inhibitor
(SNRI), has already been shown to be effective in relieving this bothersome menopausal symptom in a 12-week trial, which was reported last year.
Purpose Duloxetine, a balanced and potent serotonin and norepinephrine reuptake inhibitor
(SNRI), has been shown to be safe and effective for the treatment of women with stress urinary incontinence (SUI).
It was reported yesterday that United States-based Sunovion Pharmaceuticals has submitted a new drug application to the US Food and Drug Administration for dasotraline, a novel investigational, dual-acting dopamine and norepinephrine reuptake inhibitor